Dysplasia arising in Barrett's esophagus: Diagnostic pitfalls and natural history

Seminars in Diagnostic Pathology

Volumn 19, Issue 1, 2002, Pages 12-19

  Goldblum, John R ^a   Lauwers, Gregory Y ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Barrett's esophagus; Biomarker; Dysplasia; Intestinal metaplasia; Natural history

Indexed keywords

BIOLOGICAL MARKER;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER GRADING; CANCER RISK; CHRONIC DISEASE; DYSPLASIA; ESOPHAGUS MUCOSA; ESOPHAGUS ULCER; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; OBSERVER VARIATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INTESTINES; MALE; METAPLASIA; PRECANCEROUS CONDITIONS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036196319     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus
2. Adenocarcinoma complicating columnar epithelial-lined (Barrett's) esophagus
3. Adenocarcinoma in Barrett's esophagus: A new epidemic?
4. Esophageal cancer trends and risk factors
5. Barrett's esophagus
6. Barrett's esophagus: A review
7. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus
8. Dysplasia in Barrett's esophagus: A clinicopathologic study of six patients
9. Predictors of progression to malignancy in Barrett's esophagus: Endoscopic, histologic and flow cytometric follow-up of a cohort
10. Barrett's esophagus, dysplasia and adenocarcinoma
11. Endoscopic biopsies diagnose high-grade dysplasia or early operable adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions
12. Dysplasia in Barrett's esophagus
13. The spectrum of carcinoma arising in Barrett's esophagus: A clinicopathologic study of 26 patients
14. Barrett's esophagus: Development of dysplasia and adenocarcinoma
15. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus
16. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus
17. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia
18. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical implications
19. Superficial esophageal carcinoma
20. Interobserver variation in the diagnosis of superficial adenocarcinoma in Barrett's esophagus
21. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
22. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: A reaffirmation
23. Long-term follow-up of Barrett's high-grade dysplasia
24. A. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia
25. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression
26. Barrett's esophagus: A review of the pathologist's role in diagnosis and management
27. p53 Protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: A follow-up study
28. Accumulation of p53 protein in normal, dysplastic and neoplastic Barrett's oesophagus
29. Potential application of p53 as an intermediate biomarker in Barrett's esophagus
30. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry
31. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus. A longitudinal study
32. Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: An endoscopic study
33. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus
34. A. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations
35. Flow cytometry complements histology in detecting patients at risk for Barrett's adenocarcinoma
36. Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression
37. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
38. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus